Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Solid Biosciences Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.
- Period
- the fourth quarter and fiscal year ended December 31, 2023
- Result
- preliminary results
Exact text from the filing
Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, the Company disclosed in the Presentation that it expects to report cash, cash equivalents and available-for-sale securities of approximately $123.9 million as of December 31, 2023.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Solid Biosciences Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at aggregate gross proceeds from the Private Placement of approximately $108.9 million (effective 2024-01-08).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional accredited investors
- Value
- aggregate gross proceeds from the Private Placement of approximately $108.9 million
- Effective
- 2024-01-08
Exact text from the filing
On January 8, 2024, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 16,973,103 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.53 per share, and, to one Investor in lieu of Shares, pre-funded warrants to purchase 2,712,478 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.529 per Pre-Funded Warrant (the “ Private Placement ”).
View on SEC.gov